Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

310 results found

2026 ∙ Ministério da Saúde

Introduction of the 20-valent pneumococcal vaccine (conjugate) into the national immunization program

  • Americas
  • Brazil
  • recommendation
  • Pneumococcal disease
Download:
2026

25th Meeting of the European Technical Advisory Group of Experts on immunization (ETAGE): 17–18 November 2025

  • Europe
  • Pneumococcal disease
  • Varicella
  • Herpes zoster
Download:
2026

Recommendations for pneumococcus 2026

  • Americas
  • Pneumococcal disease
Download:
2026

Recommendations on pneumococcal vaccination to at-risk groups

  • Recommendation
  • Europe
  • Sweden
  • Risk group
  • Pneumococcal disease
Download:
2026 ∙ STIKO

Update of the STIKO recommendation on vaccination against pneumococcal disease for children and adolescents with risk factors aged ≥ 2 to 17 years

  • Recommendation
  • Europe
  • Germany
  • children
  • adolescents
  • Risk group
  • Pneumococcal disease
Download:
2025 ∙ Maggi, S. Fulop, T. De Vita, E. Limongi, F. Pizzol, D. Di Gennaro, F. Veronese, N.

Association between vaccinations and risk of dementia: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Herpes zoster
  • Tetanus
  • Diphtheria
  • Pertussis
  • Influenza
  • Pneumococcal disease
  • Poliomyelitis
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Vink, K. Kusters, J. Wallinga, J.

Chrono-optimizing vaccine administration: a systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Influenza
  • Hepatitis B
  • Hepatitis A
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Fletcher, M. A. Okasha, O. Baay, M. Syrochkina, M. Hayford, K.

Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022

  • All age groups
  • Pneumococcal disease
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Cao, B. K. Hanifa, R. S. Nguyen, T. P. Postma, M. J. van der Schans, J.

Economic evaluations of vaccines against respiratory infections in adults in Southeast Asia: A systematic review

  • South-East Asia
  • Western Pacific
  • Adults
  • Older adults
  • Influenza
  • COVID-19
  • Pneumococcal disease
  • Varicella
  • Pertussis
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Peng, R. Zhang, T. Dunne, E. M. Xu, Z. Sun, A. Cheng, J. Yang, J. Zhao, G.

Effectiveness and impact of 7 and 13-valent pneumococcal conjugate vaccines in Chinese children: A systematic review and meta-analysis

  • Western Pacific
  • China
  • Newborn
  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
Loading...